Home > Nanotechnology Columns > Bergeson & Campbell, P.C. > Explanatory Statement for EPA Appropriations Bill Directs EPA Administrator to Involve FDA in NanoEHS Research
 |
Lynn L. Bergeson Managing Director Bergeson & Campbell, P.C. |
Abstract:
On November 10, 2020, the Senate Committee on Appropriations released 12 fiscal year (FY) 2021 appropriations bills and explanatory statements.
November 12th, 2020
Explanatory Statement for EPA Appropriations Bill Directs EPA Administrator to Involve FDA in NanoEHS Research
On November 10, 2020, the Senate Committee on Appropriations released 12 fiscal year (FY) 2021 appropriations bills and explanatory statements. See https://www.appropriations.senate.gov/news/committee-releases-fy21-bills-in-effort-to-advance-process-produce-bipartisan-results The bill for the Department of the Interior, environment, and related agencies includes funding for the U.S. Environmental Protection Agency (EPA). The explanatory statement (see https://www.appropriations.senate.gov/download/fy21-interior-report ) for the bill includes language regarding nanomaterials research at EPA and states:
The Committee notes the increased capabilities that the Food and Drug Administration [FDA] has developed to study environment, health, and safety of nanomaterials [nanoEHS] within FDA's Jefferson Laboratory Campus, including the National Center for Toxicological Research, and its consolidated headquarters at White Oak, Maryland. The FDA can and should be more involved in nanoEHS research with other agencies, particularly in activities involving human health. Out of the amounts appropriated, the Administrator shall seek to involve the FDA in nanoEHS research to the maximum extent possible, including participation in EPA-funded research.
Bookmark:
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||